Why Most Clinical Supply Risk Registers Fail — and What to Track Instead

Almost every clinical program has a risk register. Very few of them prevent a single risk.

If you've spent any time in clinical supply, you know the artifact: a spreadsheet with forty rows, each scored on a probability-times-impact scale, color-coded red-amber-green, built during study start-up, presented once at a kickoff meeting, and then quietly abandoned. When something actually goes wrong six months later — a depot runs short, a comparator becomes unavailable, a lane keeps throwing excursions — people go back to the register and discover that either the risk wasn't on it, or it was on it, rated "low," and owned by no one.

That's not risk management. It's risk documentation. And the gap between the two is where trials get into trouble. Here's why most registers fail, and what disciplined teams track instead.

The four reasons risk registers fail

After enough programs, the failure pattern is remarkably consistent. It's almost always some combination of these four.

1. They're static in a system that never stops moving

A clinical supply chain changes weekly — enrollment accelerates, sites activate, a protocol amendment lands, a vendor slips. A register built once at study start-up and never revisited is describing a trial that no longer exists. By the time anyone reopens it, it's a historical document, not a working tool.

2. They're generic

Too many registers are copy-pasted from the last study. "Risk of supply delay. Risk of temperature excursion. Risk of enrollment variance." True of every trial, useful for none. A risk that isn't specific to this protocol, these countries, and this comparator tells you nothing you can act on.

3. They confuse scoring with managing

The probability-times-impact matrix feels rigorous, but it manufactures false precision. Is this risk a 3 or a 4? Nobody actually knows, so the number is invented, and then it's treated as fact. Worse, the act of scoring often becomes the deliverable — once the register is "rated," the team feels the risk work is done. It isn't. A score is not a mitigation.

4. They track lagging indicators

This is the deepest flaw. Most registers describe outcomes you want to avoid — "stockout at site," "missed dose," "rejected shipment." But by the time you can tick that box, the damage is done. A lagging indicator tells you that you failed. A leading indicator tells you that you're about to, while there's still time to act.

The shift: from a list of risks to a watchlist of signals

The teams that genuinely manage supply risk don't maintain a longer register. They maintain a shorter one — and they pair it with a small set of leading indicators they actually watch.

The mindset change is simple but profound: stop cataloguing everything that could theoretically go wrong, and start monitoring the handful of signals that tell you something is going wrong, early enough to do something about it. A focused watchlist of eight to twelve live signals beats a forty-row register every time, because people will actually look at it.

What to track instead: the leading indicators that matter

These are the signals that give you warning while you still have options. Each should have an owner, a threshold that triggers action, and a defined response — not just a number on a dashboard.

• Enrollment vs. forecast variance. The single most important early signal. When actual enrollment diverges from the forecast your supply was built on, every downstream number is now wrong. Watch the variance, not just the absolute count.
• Days of supply at each depot and site. Not "do we have stock" but "how many days of cover, given current dispensing rate." Days-of-supply turns inventory into an early-warning metric.
• Shelf-life runway vs. resupply lead time. If your remaining shelf life is shorter than the time it takes to resupply, you have a problem that hasn't surfaced yet. This gap is one of the most under-watched signals in clinical supply.
• Excursion frequency by lane. A single excursion is an event. The same lane throwing repeated excursions is a leading indicator of a systemic failure you can fix before it destroys irreplaceable product.
• Vendor on-time-in-full performance. A CMO or depot whose delivery reliability is drifting is telling you about next quarter's stockout today.
• Comparator availability and market signals. For trials that depend on a sourced comparator, market scarcity and price movement are early warnings of a supply interruption.
• IRT resupply trigger health. If your resupply automation is firing late, mis-configured, or being overridden manually, that's a process risk hiding in plain sight.

Notice what these have in common: every one of them moves before the failure, not after. That's the whole point.

Make it an operating rhythm, not an artifact

A watchlist only works if someone looks at it on a cadence. The best clinical supply leaders build a short, regular review — weekly or biweekly — where the team walks the live signals, not the static register. The questions are always the same: What moved? What crossed a threshold? Who owns the response? What do we do this week?

This is the difference between risk management as a document and risk management as a discipline. The document gets filed. The discipline gets results. A register reviewed once is theater; a handful of signals reviewed every week is control.

Keep a register — just make it earn its place

None of this means abandoning the register entirely. A lean register still has value for the genuinely strategic, low-frequency risks — a single-source supplier, a country with volatile import rules, a comparator with no alternative. The rule is simple: every row has to be specific to this trial, owned by a named person, tied to a real mitigation, and revisited on a schedule. If a row can't meet that bar, it's noise, and noise is what buries the risks that matter.